Prolactin Issues???? HELP!!!!!!!!!!!!!!!!!

[Gixxer82]

Originally Posted by pudzian2

meaning what....? I am just saying that im not going to take 20 other drugs to try and prevent gyno from forming when the cause is unknown to me and cannot be controlled by commonly followed procedures such as estrogen management etc... and that one day IF there is a serious problem behind my nips it will be cut out

have you or Jomi had flare ups when phasing in different compounds and such? did they subside on their own?

My nips got sensitive for a couple days once, I took some toremifine and it disappeared.

and i've taken almost everything under the sun lol

[sfearl1]

Originally Posted by Gixxer82

My nips got sensitive for a couple days once, I took some toremifine and it disappeared.

and i've taken almost everything under the sun lol

pfffft nooooooo not everything!

[xjsynx]

Originally Posted by Gixxer82

My nips got sensitive for a couple days once, I took some toremifine and it disappeared.

and i've taken almost everything under the sun lol

translation: I like to get corn-holed!

[NateW]

corn sounds good. I havent had any in weeks. All I eat is broccoli

[pudzian2]

Originally Posted by Gixxer82

My nips got sensitive for a couple days once, I took some toremifine and it disappeared.

and i've taken almost everything under the sun lol

haha nice man. Im definitely over-reacting

[Kernkraft]

Just a study that seems to support the cabergoline argument:

1: Clin Endocrinol (Oxf). 2006 Apr;64(4):366-70.

The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G.

CHUM Research Center, Notre-Dame Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada. omar.serri@umontreal.ca

OBJECTIVE: In view of the association of hyperprolactinaemia with insulin resistance, we hypothesized that patients with hyperprolactinaemia may present increased cardiovascular risk markers. DESIGN: Descriptive clinical trial. METHODS: Serum glucose, insulin, insulin resistance, lipids, high sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, tumour necrosis factor (TNF)-alpha and soluble E-selectin (sELAM-1) serum levels were determined in 15 patients with hyperprolactinaemia at baseline (compared with 20 healthy subjects) and after 12 weeks of cabergoline therapy (0.5-1 mg twice per week). We also measured mononuclear cell NF-kappaB activation and TNF-alpha production in a subset of subjects. RESULTS: Serum levels of prolactin (PRL), insulin, insulin resistance (HOMA-IR) index and hsCRP were significantly higher in patients than in control subjects. Markers of mononuclear cell activation did not differ between the groups. Hyperprolactinaemia, BMI and age were predictors of hsCRP. BMI was the only predictor of HOMA-IR. Cabergoline therapy significantly reduced serum PRL, insulin, hsCRP and sELAM-1 levels. CONCLUSIONS: These data suggest that hyperprolactinaemia is associated with insulin resistance related to increased BMI and low-grade inflammation independently of BMI. Short-term cabergoline therapy can reduce the inflammatory markers.

1: Horm Behav. 2006 May;49(5):673-80. Epub 2006 Feb 9.

Suppression of prolactin does not reduce infant care by parentally experienced male common marmosets (Callithrix jacchus).
Almond RE, Brown GR, Keverne EB.

Department of Psychology, University of Wisconsin, 1202 West Johnson Street, Madison, WI 53706, USA. almond@wisc.edu

High levels of prolactin have been found to correlate with the expression of paternal care in a variety of taxa. However, in mammals, there is little experimental evidence that prolactin is causally involved in the stimulation or maintenance of paternal care. Here, we suppressed prolactin production in paternally experienced common marmoset fathers in their family groups during the first 2 weeks after their infants were born. Circulating prolactin levels were suppressed using cabergoline (Dostinex: Pfizer), a long acting dopamine (D2) agonist with minimal behavioural side-effects. A within-subject design was used to compare behavioural and hormonal data on 5 paternally experienced fathers during two consecutive births. Cabergoline reduced prolactin to negligible levels in all fathers without effecting testosterone, DHT and cortisol and without adverse side-effects. However, lowering prolactin had no significant effect on the expression of majority of the behaviour patterns associated with paternal care. These included infant carrying, infant grooming and the frequency with which fathers retrieved and rejected infants. The only infant-related behaviour to be affected was the frequency with which fathers touched, licked and investigated infants. We noted a marginally significant increase in this behaviour during cabergoline treatment. Despite the lack of effect on paternal care, cabergoline did exert an effect on the affiliative/sexual behaviour of fathers as there was a significant increase in the grooming behaviour fathers directed at and received from their mates during drug treatment. This study showed that experienced male marmosets can express paternal behaviour in the absence of the high prolactin levels normally seen after infants are born.

[Kernkraft]

Last find before I finally head off to bed:

Quinagolide as an alternative option to treat hyperprolactemia as well:

Quinagolide - a valuable treatment option for hyperprolactinaemia -- Barlier and Jaquet 154 (2): 187 -- European Journal of Endocrinology

[dontknowaboutme]

Originally Posted by xjsynx

translation: I like to get corn-holed!

ROFL!

nice one.